High impact
Johnson & Johnson says 2026 adjusted operational EPS and adjusted EPS are expected to decrease by $0.64, and 2027 adjusted operational EPS and adjusted EPS are expected to decrease by $1.36, per SEC filing.
FirstSquawk07/30, 04:29 AM
Related assets
Coming up for JNJ
Explore next
Latest JNJ news
Finnhub08/27, 12:50 PM
Johnson & Johnson's autoimmune drug received FDA approval for treatment of a rare blood disease.
FirstSquawk08/08, 08:14 AM
Duato sold 41,957 J&J shares at an average price of $258.06.
FirstSquawk08/08, 08:13 AM
J&J's Duato disclosed a share sale of $1.69M at an average price of $258.74.